Novavax: COVID-19 trials

The registry lists 20 COVID-19 studies with Novavax as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 2Phase 2 10Phase 3 13Phase 4 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase 3 Adolescent Study for SARS-CoV-2 rS Variant VaccinesCompletedNCT05973006Phase 3Results posted
• Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA VaccinesCompletedNCT05875701Phase 3Results posted
• Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in AdultsCompletedNCT05463068Phase 3Results posted
• Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination VaccineCompletedNCT04961541Phase 1/2Results posted
• Efficacy and Safety of NVX-CoV2705TerminatedNCT07086222Phase 4
• Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United StatesCompletedNCT06633835Phase 4
• Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza VaccineWithdrawnNCT06485752Phase 2/3
• Lot Consistency Study of COVID-19 and Influenza Combination VaccineWithdrawnNCT06482359Phase 2/3
• A Strain Change Study for SARS-CoV-2 rS VaccinesCompletedNCT06409663Phase 3
• A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination VaccineCompletedNCT06291857Phase 3
• A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.CompletedNCT05975060Phase 2/3
• Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS VaccinesCompletedNCT05925127Phase 2/3
• A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination VaccineCompletedNCT05519839Phase 2
• Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 YearsCompletedNCT05468736Phase 2/3
• Phase 3 Boosting Study for the SARS-CoV-2 rS Variant VaccinesCompletedNCT05372588Phase 3
• A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)CompletedNCT05112848Phase 2
• Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in AdultsWithdrawnNCT05029856Phase 1/2
• A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2CompletedNCT04611802Phase 3
• A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United KingdomCompletedNCT04583995Phase 3
• A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African AdultsCompletedNCT04533399Phase 2